Thursday, 29 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Business Update

Cohance Lifesciences Business Update

Cohance Lifesciences completed a USFDA inspection of its Shamshabad formulation plant, receiving a Form 483 with four observations. The company is initiating corrective measures.

Source

BSE filing, NSE: COHANCE. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Cohance Lifesciences Ltd: key numbers

Share price
₹476.05
Market cap
₹18,214 Cr
Revenue (annual)
₹2,269 Cr
Net profit (annual)
₹179.2 Cr
P/E (TTM)
171.4×Sector 46.1×
Promoter holding
57.48%-0.01% QoQ
FII holding
7.71%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Cohance Lifesciences Ltd

All →

Other business update announcements

All →